Autolus report initial results for cutting-edge cell therapy for cancer

7 Dec 2018, 10:11 a.m.

Professor Persis Amrolia, Consultant in Bone Marrow Transplant at Great Ormond Street Hospital (GOSH)

Clinical trials of a pioneering new cancer therapy known as AUTO3, developed by UCL spinout company Autolus Therapeutics, have shown positive initial results.AUTO3, which is part of a new generation of personalised ‘CAR-T’ cancer therapies, works by genetically modifying a patient’s own immune cells to recognise and destroy cancer cells. Immune cells are taken from the patient’s blood and modified to target a specific molecule found on the surface of cancer cells.

Great Ormond Street Hospital (GOSH) has been at the forefront of research in to CAR-T cell therapy for children with leukaemia with three active clinical trials. CD19 CAR-T cells have shown remarkable results in children with otherwise incurable ALL and have recently been licensed by NHS England. However, approximately 50% of patients relapse because the leukaemia evolves to down-regulate the CD19 target on leukaemic cells. AUTO3 is the first CAR-T therapy to simultaneously target two different molecules – CD19 and CD22 – which could reduce the chance of relapse after CAR T cell therapy.

The AMELIA trial found that AUTO3 was well-tolerated and safe for use in children with the rare form of blood cancer, acute lymphoblastic leukaemia (ALL).

“AUTO3 appears to have a manageable safety profile, with the potential to overcome target-negative relapse, a major limitation of current CD19-targeted therapies," said Professor Persis Amrolia, lead investigator and Consultant in Bone Marrow Transplant at Great Ormond Street Hospital (GOSH) and NIHR Research Professor of Transplantation Immunology at UCL Great Ormond Street Institute of Child Health (ICH).

AMELIA, which is a multicentre phase I/II study led by GOSH in the UK, aims to treat 54 children in total and will evaluate the safety and optimal dose of AUTO3 for patients. 10 children with relapsed ALL have so far been treated and eight of these patients entered remission.

The interim results for both AUTO3 trials were presented at the American Society of Haematology (ASH) annual meeting earlier this month.

Ancient gene mutation found as the cause of rare hereditary condition for GOSH patient.

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).

Scientists build whole functioning thymus from human cells

Researchers from two leading national organisations have rebuilt a human thymus using human stem cells and a bioengineered scaffold thanks to support from the NIHR GOSH Biomedical Research Centre (BRC). Their work, which has been published in Nature Commu

Leukaemia trial shows promise and complexity of genome-edited cell therapies

A ‘one size fits all’ immune therapy developed at the UCL Great Ormond Street Institute of Child Health (ICH) could help to clear cancerous cells in children and adults who have exhausted all other treatment options for B-cell acute lymphoblastic leukaemi

GOSH researchers join experts in warning of the detrimental impact of a no deal Brexit on rare diseases

Experts have warned that a ‘no deal’ Brexit will result in the exclusion of the UK from the 24 European Reference Networks (ERNs) that were established to improve the care of patients bearing the lifelong burden of a rare disease, which require highly spe